Key causes of preventable deaths in New Zealand In a population of 10,000 New Zealanders, every year there will be about:
|
|
- Brittney Reeves
- 5 years ago
- Views:
Transcription
1 Preventive care - Chronic Disease Management in primary care: a population perspective Rod Jackson University of Auckland New Zealand (22/11/8) Key causes of preventable deaths in New Zealand In a population of 1, New Zealanders, every year there will be about: 1 coronary & stroke deaths 1 diabetic death 1 breast cancer death 1 prostate cancer death 1 suicide every year 1 road traffic death (1 cervical cancer death every 5 years) NZHIS annual mortality statistics Burden of disease in NZ: IHD Stroke CORD Diabetes Depression Asthma Anxiety Lung cancer Road traffic Colorectal ca Dementia Breast ca Suicide/self harm LRTI Osteoarthritis Hearing disorders Prostate ca Substance Burden of dise Due to disease and injury outcome (No. DALYs/1) Peripheral arterial Lymphoma/myeloma Martin Tobias MoH 23 Vascular disease management 1
2 The main causes of CHD & stroke smoking* Burden of disease in NZ: 8 Due to risk factors (No. deaths) Tobacco Cholesterol high blood cholesterol / saturated fat diet* Blood pressure Body mass index Physical inactivity Microbes (infection) Inadequate F&V intake Diabetes high blood pressure* * these 3 factors explain most events in populations Alcohol Violence Other injury hazards Road traffic crashes Radiation (ultraviolet) Sexual behaviours Illicit drug use Martin Tobias MoH 23 4 Smoking prevalence in NZ: P e r c e n t 6 Smoking prevalence in NZ by ethnicity P e r c e n t % % Y e a r year 1 M_o r i Pacific peoples European/Other Y e a r year Blood cholesterol & CHD death CHD PSC. Lancet 27; 37:
3 CHD: A. HDL; B. non-hdl; & C. TC/HDL Trends in TC/HDL ratio in Auckland CHD PSC. Lancet 27; 37: Metcalf et al. NZMJ 26 Blood pressure & IHD Type 2 Diabetes is not a disease! 4. Total stroke 4. Total ischaemic heart disease 4. Cardiovascular death Hazard ratio & 95% CI Usual fasting glucose (mmol/l) PSC. Lancet 22; 36: Asia Pacific Cohort Studies Collaboration. Diabetes Care 24;27: The average NZder is overweight Everyone is getting fatter The optimal BMI Metcalf et al. NZMJ 17 November 26, Vol 119 No URL: Metcalf et al. Auckland studies (unpublished) 3
4 CHD mortality trends in year-old New Zealanders Stroke mortality trends in year-old New Zealanders Contribution of changes in risk factors to trends in CHD in New Zealand Tobias et al. ANZJPH 28;32: Estimated trends in systolic blood pressure by sex, New Zealand: ; standardised for age (35-64 years) Estimated trends in blood cholesterol by sex, New Zealand: ; standardised for age (35-64 years) 4
5 Estimated trends in tobacco smoking by sex, New Zealand: ; standardised for age (35-64 years) Estimated contribution of risk factor changes to CHD trends by sex, New Zealand: ; standardised for age (35-64 years) 22% 31% 2% 73% 15% 35% 39% 87% Trends in systolic blood pressure in normal, overweight & obese Aucklanders NZ & Japan: CHD mortality yrs Metcalf et al. unpublished 28 Annual deaths per 5, people Annual deaths from IHD per 5, 5-64 yrs: Australia men NZ men Year 5
6 Please put out that cigarette, grandpa Offer brief advice and NRT to all smokers every time you see them! Ashley Bloomfield MoH 28 Source: Jamrozik K, Dobson A, Tobacco Control, August 1999 Advise all patients to eat less SF Per capita availability of butter 23 Sources of saturated fat in New Zealand diet 1.9 kg/person per yr 3.2 kg/person per yr Eat less salt Aspirin + Statin + BP drugs = > 5% CVD Aspirin Statin ACEI ± Diuretic ± BB ± CCB 6
7 Benefit of treatment is directly proportional to the pre-treatment risk Difficult to estimate risk in your head Absolute CVD risk by SBP ± other risk factors Usage of CVD risk charts by GPs in NZ: ; after 6 yrs of risk-based guidelines n= 5 (RR =83%) Never 6% < once per month 39% About once per month 24% > twice per month 31% Jackson et al. Lancet :434-4 Arroll. N Z Fam Physician. 22;117: Percentage on combined BP & lipid lowering medication by 5 year absolute CV risk: % on BP & C medication CV 1 history 2% <2% <15% <1% <5% 6 Risk 7 not estimable Unpublished data Risk could only be estimated on 1/3 patients Impact of electronic decision support in 1 o care % documented 16% 14% 12% 1% 8% 6% 4% 2% % Documentation of 5yr absolute CVD risk pre Prompt Audit time period post Prompt CVD risk nonmaori CVD risk Maori Wells S et al. Eur J Cardiovasc Prev Rehab 28;15:
8 Framingham predicted versus observed CVD event rates in NZ primary care (35-74 yrs) OBSERVED (Cumulative incidence (%) of CVD event in 5 years (95%CI)) Framingham Performance: Threshold Discrimination Event rates by risk category 1% 13% 9% 7% 8% 1% 53% 7% 6% Hx CVD 15+% 5% 1-<15% 4% 11% <1% 7% 3% 11% 2% 24% 1% PREDICTED (Framingham score, 5-year risk, %) Preliminary analyses on PREDICT patient population, personal communication Sue Wells 28 % % of total people (n=44842) % of total events (n=2314) Preliminary analyses on PREDICT patient population, personal communication Sue Wells 28 8
Cardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationProfessor Norman Sharpe. Heart Foundation West Coast
Professor Norman Sharpe Heart Foundation West Coast Primary Care the Keystone to Heart Health Improvement Norman Sharpe June 2013 The heart health continuum and the keystone position The culprit disease
More informationHEALTH TARGETS IN PRIMARY CARE
HEALTH TARGETS IN PRIMARY CARE MORE HEART AND DIABETES CHECKS BETTER HELP FOR SMOKERS TO QUIT Better Help for Smokers to Quit 90% of enrolled patients who smoke and are seen by General Practice, will be
More informationShould we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand
Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand Presentation outline Strengths & weaknesses of short-term risk approach Strengths &
More informationVascular Diseases. Overview: Selected Slides
Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates
More informationBeyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital
Beyond Framingham Prediction of cardiovascular risk Niels van Pelt Cardiologist, Middlemore Hospital Niels Bohr (Danish Physicist)1885-1962 Prediction is very difficult, especially if it's about the future
More information2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.
2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension Writing Group: Background Hypertension worldwide causes 7.1 million premature
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More informationEconomically efficient approaches to address chronic disease in developing countries
Economically efficient approaches to address chronic disease in developing countries Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Brigham & Women s Hospital Harvard Medical School Center
More informationReducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf
Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf Disclosure None Polypill & CVD Prevention 1. Why do we need a polypill? 2. What components in the polypill?
More informationCurrent Issues in Cardiovascular Risk Management. Les Toop Norman Sharpe June 2014
Current Issues in Cardiovascular Risk Management Les Toop Norman Sharpe June 2014 Risk assessment is just the beginning of a conversation Les Toop Department of General Practice, University of Otago, Christchurch
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationThe cost-effectiveness of polypharmacy
The cost-effectiveness of polypharmacy 25 September 2012 Thomas A. Gaziano MD MSc Division of Cardiovascular Medicine Harvard Medical School Program for Health Decision Science Harvard School of Public
More informationRisk Factors for NCDs
Risk Factors for NCDs Objectives: Define selected risk factors such as; tobacco use, diet, nutrition, physical activity, obesity, and overweight Present the epidemiology and significance of the risk factors
More informationBEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS
BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS Neil R Poulter ICCH, Imperial College London BHIVA: October 10th, 2008 Background CVD is the biggest single killer in the world CVD rates are increasing High
More informationPopulation models of health impact of combination polypharmacy
Population models of health impact of combination polypharmacy Global Summit on Combination Polypharmacy for CVD, 25 th September 2012 Dr Mark Huffman Northwestern University, Chicago Charity No: 1110067
More informationEthnic inequalities in mortality: Trends and explanations,
Pharmac, Oct 2009 Professor Tony Blakely Ethnic inequalities in mortality: Trends and explanations, 1981-2004 Acknowledgments: Tobias, Atkinson, Woodward, and too many more to name 1 Index Structure of
More informationNHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell
NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Understanding of the cardiovascular system 2. Describe the most common types of
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationHeart Age and Cardiovascular Risk
Heart Age and Cardiovascular Risk Mark Cobain Unilever R+D Colworth Science Park Sharnbrook Bedfordshire Europrevent, Geneva April 16 2011 Conflict of Interest Statement Employment by Unilever PLC A producer
More informationNHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell
NHS Health Check Training for Healthy Living Centre Staff and Colleagues. June 2015 Amanda Chappell Aim of the session 1. Increase your understanding of the cardiovascular system 2. Describe the most common
More informationSocioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women
Socioeconomic status and the 25x25 risk factors as determinants of premature mortality: a multicohort study of 1.7 million men and women (Lancet. 2017 Mar 25;389(10075):1229-1237) 1 Silvia STRINGHINI Senior
More informationAssociate Professor Gerry Devlin
Associate Professor Gerry Devlin Clinical Cardiologist and Interventional Cardiologist NZ Heart Foundation Hamilton 9:00-9:15 Secondary Prevention of IHD The Challenge of Secondary Prevention Associate
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationGetting serious about preventing cardiovascular disease
Getting serious about preventing cardiovascular disease Southwark s Experience Professor Kevin Fenton Director of Health and Wellbeing, London Borough of Southwark February 2018 Twitter: @ProfKevinFenton
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationEuroPrevent 2010 Fatal versus total events in risk assessment models
EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationSIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence
SIGN 149 Risk estimation and the prevention of cardiovascular disease Quick Reference Guide July 2017 Evidence ESTIMATING CARDIOVASCULAR RISK R Individuals with the following risk factors should be considered
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationAbsolute cardiovascular disease risk management
Quick reference guide for health professionals Absolute cardiovascular disease risk management This quick reference guide is for use by health professionals for primary prevention of cardiovascular disease
More informationPrevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini
Prevenzione cardiovascolare e cambiamento degli stili di vita Gian Franco Gensini Main causes of death worldwide at all ages (year:: 2005) 17.5 milion Preventing Chronic Diseases A vital investiment. WHO
More informationIdentification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More information!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants
Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise
More informationDr Chris Ellis. Consultant Cardiologist Auckland
Dr Chris Ellis Consultant Cardiologist Auckland CVD Risk Prevention in NZ 2013 & Beyond: The Clinicians View Dr Chris Ellis Cardiologist Green Lane CVS Service, Cardiology Department, Auckland City Hospital
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationWhat s new in cardiovascular disease risk assessment and management for primary care clinicians
Cardiovascular system What s new in cardiovascular disease risk assessment and management for primary care clinicians The recently released 2018 Cardiovascular Disease Risk Assessment and Management for
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationIschaemic Heart Disease
Ischaemic Heart Disease Katherine Rothwell Case 1 65 yr old female PMHx : Eczema, is a smoker 20/day Comes to see you complaining of central chest pain Present past few months. Comes on when gardening
More informationManagement of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB
Management of Hypertension for Stroke Prevention in New Zealand: Can We Do Better? Walter van der Merwe Nephrologist Waitemata DHB Increasing stroke numbers in New Zealand an 'epidemic' says leading AUT
More informationImplementing Type 2 Diabetes Prevention Programmes
Implementing Type 2 Diabetes Prevention Programmes Jaakko Tuomilehto Department of Public Health University of Helsinki Helsinki, Finland FIN-D2D Survey 2004 Prevalence of previously diagnosed and screen-detected
More informationYour Name & Phone Number Here! Longevity Index
Your Name & Phone Number Here! Longevity Index Your Health Risk Analysis is based on a variety of medical and scientific data from organizations such as the American Heart Association, American Dietetic
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationBriefing to the Health Committee Enquiry on the Early Diagnosis and Treatment of Prostate Cancer
Briefing to the Health Committee Enquiry on the Early Diagnosis and Treatment of Prostate Cancer Prostate Specific Antigen (PSA) Testing in New Zealand Background 1. The Committee have requested information
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic
1 U.S. Department of Health and Human Services National Institutes of Health Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationDepok-Indonesia STEPS Survey 2003
The STEPS survey of chronic disease risk factors in Indonesia/Depok was carried out from February 2003 to March 2003. Indonesia/Depok carried out Step 1, Step 2 and Step 3. Socio demographic and behavioural
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationMedtech Training Guide
Medtech Training Guide Clinical Audit Tool Copyright Medtech Limited Page 1 of 80 Clinical Audit Tool v4.0 Contents Chapter 1: Getting Started... 3 Logging In... 3 Logging Out... 3 Setting the Preliminary
More informationSection 3: Health and Independence Report 2013
Section 3: Health and Independence Report 2013 Purpose of this report The Health and Independence Report (the Report) gives an overview of the current state of public health in New Zealand. It has three
More informationFive chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationImplementing population based screening programs
Implementing population based screening programs Based on integrated risk profiling Dr. R.A. Kraaijenhagen Health expectancy Life expectancy Men: 75,5 Women: 80,6 Health expectancy Men: 61,3 (last 14 years
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationLecture Chronic Non-Communicable Diseases Epidemiology, Risk factors of NCD
Faculty of Medicine Epidemiology and Biostatistics الوبائيات واإلحصاء الحيوي (31505204) Lecture 20-21 Chronic Non-Communicable Diseases Epidemiology, Risk factors of NCD By Hatim Jaber MD MPH JBCM PhD
More informationImpact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University
More informationThe Health Status of Māori Male Prisoners: Key results from the Prisoner Health Survey 2005
The Health Status of Māori Male Prisoners: Key results from the Prisoner Health Survey 2005 2008 Summary Almost 50% of sentenced male prisoners are Māori. Forty-seven percent of Māori male prisoners have
More informationReducing risk in heart disease
Reducing risk in heart disease An expert guide to clinical practice for secondary prevention of coronary heart disease Prof Patricia Davidson (chair) Prof Nigel Stocks Dr Anu Aggarwal Ms Jill Waddell Ms
More informationThe local healthcare system: Focusing on health
The local healthcare system: Focusing on health Sian Griffiths Professor of Public Health Director of the School of Public Health Chairman, Department of Community and Family Medicine The Chinese University
More informationDr Johan Morreau. Paediatrician Rotorua
Dr Johan Morreau Paediatrician Rotorua Smoking in pregnancy Implications for the baby (and mother) Johan Morreau 2013 Major Issue Lifelong implications More important than the BP a Paediatrician s perspective
More informationRisk Factors for Heart Disease
Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress
More informationUsing Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O.
Using Coronary Artery Calcium Score in the Quest for Cardiac Health Robert J. Hage, D.O. Heart disease is the leading cause of death in the United States in both men and women. About 610,000 people die
More informationEstablished Risk Factors for Coronary Heart Disease (CHD)
Getting Patients to Make Small Lifestyle Changes That Result in SIGNIFICANT Improvements in Health - Prevention of Diabetes and Obesity for Better Health Maureen E. Mays, MD, MS, FACC Director ~ Portland
More informationClinical Audit Tool. Release Notes
Clinical Audit Tool Version 1.0.46 (July 2013) Release Notes These Release Notes contain important information for all Medtech Users. Please ensure that they are circulated amongst all your staff. We suggest
More information10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None
MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH None 1 Objectives Why the need for change in the guidelines? What is the potential impact of these guidelines? Where do we go from here?
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association Cardiovascular treatment gaps: closing, but slowly Vanessa Selak, Natasha Rafter, Varsha Parag, Andrew Tomlin, Stephen Vander
More informationCorporate Health Screening
Corporate Health Screening What should I look out for? Presented by: Dr Wee Wei Keong Director Health for Life Programme WHAT IS HEALTH SCREENING? Tests/procedures carried out to detect a condition/disease
More informationTHE NEW ZEALAND MEDICAL JOURNAL
THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association What proportion of cancer is due to obesity? Tony Blakely, Diana Sarfati, Caroline Shaw The evidence linking overweight and
More informationThe Importance of Local Research in Developing Health Strategy The Case of Cardiovascular Disease Prevention in Sri Lanka
The Importance of Local Research in Developing Health Strategy The Case of Cardiovascular Disease Prevention in Sri Lanka Dr Ravi P. Rannan-Eliya, Dr Nilmini Wijemanne Institute for Health Policy KDU International
More informationALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial
1 ALLHAT Role of Diuretics in the Prevention of Heart Failure - The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial Davis BR, Piller LB, Cutler JA, et al. Circulation 2006.113:2201-2210.
More informationCardiovascular disease, studies at the cellular and molecular level. Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009
Cardiovascular disease, studies at the cellular and molecular level Linda Lowe Krentz Bioscience in the 21 st Century September 23, 2009 Content Introduction The number 1 killer in America Some statistics
More informationBlood Pressure Acre Surgery Diviash Thakrar
Blood Pressure Acre Surgery Diviash Thakrar Why Are We Doing This? 1. Improve education for patients within the practice 2. Allow us use this for general health promotion Raise money for charity 3. Raise
More informationChapter 6: Combined Cardiovascular Risk Factors
Chapter 6: Combined Cardiovascular Risk Factors Key points Cardiovascular diseases such as coronary heart disease and stroke cause 44% of all deaths in New Zealand. The 1996/97 Health Survey provides information
More informationPrimary Care Smoking Cessation. GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco
Primary Care Smoking Cessation Dr John McMenamin GP and Clinical Director WRPHO Primary Care Advisor MOH Tobacco Team Target Champion Primary Care Tobacco Target or Tickbox? The Tobacco health target:
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationSecondary analyses of HSE data and linked health outcomes - an overview of work in progress. UCL (University College London)
Secondary analyses of HSE data and linked health outcomes - an overview of work in progress Dr Jennifer Mindell, UCL (University College London) Linked HSE mortality data (2008) In 2008, some mortality
More informationCLINICAL PRACTICE EVALUATION I: MEDICAL RECORD REVIEW (Adult Patient Population)
Diplomate: CLINICAL PRACTICE EVALUATION I: MEDICAL RECORD REVIEW (Adult Patient Population) A. RECORD IDENTIFIER INFORMATION 1. Date medical record reviewed (mm/dd/year) / / 2. Patient identifier: 3. Date
More informationBridging health promotion intervention policy with behavioral risk factor surveillance in Thailand
Bridging health promotion intervention policy with behavioral risk factor surveillance in Thailand The 7 th World Alliance for Risk Factor Surveillance (WARFS) Global Conference Toronto, Ontario, Canada,
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationHeart Disease Genesis
Heart Disease Genesis The Ultimate Lecture on CAD origins Petr Polasek MD FRCPC FACC Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More information(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects
Table 1. Distribution of baseline characteristics across tertiles of OPG adjusted for age and sex (n=6279). Continuous variables are reported as mean with 95% confidence interval and categorical values
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationmajor public health burden
HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing
More informationWe acknowledge the traditional custodians of the land on which we meet today and pay respect to Elders past, present and emerging.
We acknowledge the traditional custodians of the land on which we meet today and pay respect to Elders past, present and emerging. We also extend that respect to other Aboriginal and/or Torres Strait Islanders
More information